California Breast Cancer Research Program Report issue

Government Phase 2

Organization Overview

First Clinical Trial
2010
NCT01219075
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

atorvastatin (lipitor) (1 trial)

Drugs in Other Trials (1)

soy isoflavones (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Cardiotoxicity (Phase 2)

Heart Diseases (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2